Saturday 17 October 2026
Export CLDI’s income statement to Excel — free account
Calidi Biotherapeutics, Inc.
CLDI Healthcare Biotechnology
Calidi Biotherapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $45,000.00. In the quarter to June 2026, EPS grew 90.8%, free cash flow grew 11.2% and total debt fell 7.87%, each against the same quarter a year earlier.
0.84
0.03
−3.45%
Follow CLDI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (900.56%) | (408.86%) | (893.28%) | 1,970.77% |
+8 more TTM periods Free account |
|
| (283.36%) | (202.88%) | (222.05%) | (247.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(790.80%) | (585.03%) | (824.60%) | (383.30%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(12.60) | (28.55) | (79.63) | (70.97) | |
Free Cash Flow |
(17.84) | (18.40) | (21.41) | (21.77) | |
Capital Expenditures |
(0.09) | (0.12) | (0.12) | (0.10) | |
| Other line items | |||||
Cash ROIC |
(224.04%) | (149.40%) | (211.38%) | (118.50%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(114.43) | (111.94) | (97.78) | (58.24) | |
Operating CF/Net income |
0.76 | 0.73 | 0.83 | 0.85 | |
Depreciation/Fixed assets |
2.21 | 2.22 | 2.11 | 1.91 | |
Capex/Depreciation |
(0.05) | (0.07) | (0.07) | (0.06) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(12.54) | (28.37) | (79.19) | (70.66) | |
Capex per Share |
(0.07) | (0.18) | (0.45) | (0.31) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates